Mylan receives DCGI approval for TB drug pretomanid
Bio Spectrum|September 2020
Mylan receives DCGI approval for TB drug pretomanid
Mylan, a global pharmaceutical company, recently announced that the Drug Controller General of India (DCGI) has approved the anti-tuberculosis drug pretomanid for conditional access under the National Tuberculosis Elimination Programme (NTEP), making India the second country in the world to provide regulatory approval for this product.

articleRead

You can read up to 3 premium stories before you subscribe to Magzter GOLD

Log in, if you are already a subscriber

GoldLogo

Get unlimited access to thousands of curated premium stories, newspapers and 5,000+ magazines

READ THE ENTIRE ISSUE

September 2020